# UNITED STATES <br> SECURITIES AND EXCHANGE COMMISSION <br> Washington, D.C. 20549 

$\qquad$

## FORM 8-K

## CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2021

## QUANEX BUILDING PRODUCTS CORPORATION

(Exact name of registrant as specified in its charter)

## Delaware

(State or Other Jurisdiction of Incorporation)
$\qquad$

001-33913
(Commission File Number)

26-1561397
(I.R.S. Employer Identification No.)

> 1800 West Loop South, Suite 1500
> Houston, Texas 77027
> (Address of Principal Executive Offices) (Zip Code)
> (713) 961-4600
> (Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
$\square$ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| :---: | :---: | :---: |
| Common Stock, par value $\$ 0.01$ per share | NX | New York Stock Exchange |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( $\$ 230.405$ of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company $\square$
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

On September 2, 2021, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

## Item 9.01. Financial Statements and Exhibits.

99.1 Press Release dated September 2, 2021

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## Quanex Building Products Corporation

# Quanex Building Products Announces Third Quarter 2021 Results and Reaffirms Full Year 2021 Guidance 

Solid Net Sales Growth Realized Across All Operating Segments Strong Balance Sheet<br>Liquidity Continues to Increase<br>Repaid \$15 Million of Bank Debt

HOUSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Quanex Building Products Corporation (NYSE:NX) ("Quanex" or the "Company") today announced its results for the three months ended July 31, 2021.

The Company reported the following selected financial results:
QUANEX BUILDING PRODUCTS CORPORATION
Q3 2021 Earnings Release

| (\$ in millions, except per share data) | 2020 | 2021 | 2020 |
| :---: | :---: | :---: | :---: |
| Net Sales | \$212.1 | \$780.4 | \$596.2 |
| Gross Margin | \$49.7 | \$175.7 | \$126.6 |
| Gross Margin \% | 23.4\% | 22.5\% | 21.2\% |
| Net Income | \$10.8 | \$36.0 | \$16.3 |
| Diluted EPS | \$0.33 | \$1.08 | \$0.50 |
| Adjusted Net Income | \$11.1 | \$37.8 | \$18.7 |
| Adjusted Diluted EPS | \$0.34 | \$1.13 | \$0.57 |
| Adjusted EBITDA | \$27.7 | \$89.5 | \$65.2 |
| Adjusted EBITDA Margin \% | 13.1\% | 11.5\% | 10.9\% |
| Cash Provided by Operating Activities | \$45.1 | \$47.4 | \$47.6 |
| Free Cash Flow | \$40.7 | \$31.4 | \$26.9 |
| (See Non-GAAP Terminology Definitions and Disclaimers section, Non-GAAP Financial Measure Disclosure table, Selected Segment Data table and Free Cash Flow Reconciliation table for additional information) |  |  |  |
| George Wilson, President and Chief Executive Officer, stated, "Demand for our products remained robust across all of our product lines throughout the third quarter of 2021. On a consolidated basis, net sales increased by approximately $32 \%$ year-over-year as compared to the third quarter of 2020. General inflation, time lag for index pricing, supply chain challenges and labor constraints all continue to have a negative impact on margins. In addition, our plant in Germany was down for approximately 14 days during the quarter due to flooding in Europe, but the plant was back up and running at full capacity by the end of July. Our balance sheet continues to strengthen, and we were able to repay $\$ 15.0$ million in bank debt during the quarter while also repurchasing approximately $\$ 1.8$ million of our common stock. We will remain focused on generating cash and paying down debt in the near-term." (See Non-GAAP Terminology Definitions and Disclaimers section for additional information) |  |  |  |

## Third Quarter 2021 Results Summary

The Company reported net sales of $\$ 279.9$ million during the three months ended July 31, 2021, which represents growth of $32.0 \%$ compared to $\$ 212.1$ million for the same period of 2020. The increase was largely due to increased demand across all product lines and operating segments combined with increased pricing mostly related to the pass through of raw material cost inflation. In detail, Quanex posted net sales growth of $20.8 \%$ in its North American Fenestration segment, $19.3 \%$ in its North American Cabinet Components segment and $85.8 \%$ in its European Fenestration segment, excluding the foreign exchange impact and despite the challenges presented by flooding in Germany as previously noted. As a reminder, both of Quanex's manufacturing facilities in the U.K. were shut down in late March of 2020 and did not resume operations until mid-to-late May 2020. (See Sales Analysis table for additional information)

The increase in earnings for the third quarter of 2021 was mainly due to higher volumes and improved operating leverage. This increase was somewhat offset by inflationary pressures and an increase in selling, general and administrative expenses, which was mostly attributable to more normalized medical costs combined with an increase in stock-based compensation expense.

## Balance Sheet \& Liquidity Update

As of July 31, 2021, Quanex had total debt of $\$ 74.0$ million and its leverage ratio of Net Debt to LTM Adjusted EBITDA improved to 0.2x. (See Non-GAAP Terminology Definitions and Disclaimers section and Net Debt and LTM Adjusted EBITDA reconciliation tables for additional information)

The Company's liquidity increased to $\$ 306.2$ million as of July 31, 2021, consisting of $\$ 43.7$ million in cash on hand plus availability under its Senior Secured Revolving Credit Facility due 2023, less letters of credit outstanding.

## Share Repurchases

Quanex's Board of Directors authorized a $\$ 60$ million share repurchase program in September of 2018. Repurchases under this program will be made in open market transactions or privately negotiated transactions, subject to market conditions, applicable legal requirements, and other relevant factors. The program does not have an expiration date or a limit on the number of shares that may be repurchased. The Company repurchased 74,257 shares of common stock for approximately $\$ 1.8$ million at an average price of $\$ 23.88$ per share during the three months ended July 31, 2021. As of July 31, 2021, approximately $\$ 5.4$ million remained under the existing share repurchase authorization.

George Wilson, President and Chief Executive Officer, commented, "While we remain optimistic on the demand outlook for our products, we do expect inflation, labor costs, and supply chain challenges to continue pressuring margins throughout the fourth quarter of this year. We continue to pass these incremental costs along to our customers through indexes, surcharges, and price increases; however, there are time lags in each case. With this backdrop, on a consolidated basis, we are reaffirming net sales guidance of approximately $\$ 1.04$ billion to $\$ 1.06$ billion and Adjusted EBITDA* of $\$ 125$ million to $\$ 130$ million in fiscal 2021."
*When Quanex provides expectations for Adjusted EBITDA on a forward-looking basis, a reconciliation of the differences between the nonGAAP expectations and corresponding GAAP measures is generally not available without unreasonable effort. Certain items required for such a reconciliation are outside of the Company's control and/or cannot be reasonably predicted or estimated, such as the provision for income taxes.

## Conference Call and Webcast Information

The Company has scheduled a conference call for Friday, September 3, 2021, at 11:00 a.m. ET (10:00 a.m. CT). To participate in the conference call dial (877) 388-2139 for domestic callers and (541) 797-2983 for international callers, in both cases using the conference passcode 6642169, and ask for the Quanex call a few minutes prior to the start time. A link to the live audio webcast will also be available on the Company's website at http://www.quanex.com in the Investors section under Presentations \& Events. A telephonic replay of the call will be available approximately two hours after the live broadcast ends and will be accessible through September 10, 2021. To access the replay dial (855) 8592056 for domestic callers and (404) 537-3406 for international callers, in both cases referencing conference passcode 6642169.

## About Quanex

Quanex Building Products Corporation is an industry-leading manufacturer of components sold to Original Equipment Manufacturers (OEMs) in the building products industry. Quanex designs and produces energy-efficient fenestration products in addition to kitchen and bath cabinet components. For more information contact Scott Zuehlke, Senior Vice President, Chief Financial Officer \& Treasurer, at 713-877-5327 or scott.zuehlke@quanex.com.

## Non-GAAP Terminology Definitions and Disclaimers

Adjusted Net Income (defined as net income further adjusted to exclude purchase price accounting inventory step-ups, transaction costs, certain severance charges, gain/loss on the sale of certain fixed assets, restructuring charges, asset impairment charges, other net adjustments related to foreign currency transaction gain/loss and effective tax rates reflecting impacts of adjustments on a with and without basis) and Adjusted EPS are non-GAAP financial measures that Quanex believes provide a consistent basis for comparison between periods and more accurately reflects operational performance, as they are not influenced by certain income or expense items not affecting ongoing operations. EBITDA (defined as net income or loss before interest, taxes, depreciation and amortization and other, net) and Adjusted EBITDA (defined as EBITDA further adjusted to exclude purchase price accounting inventory step-ups, transaction costs, certain severance charges, gain/loss on the sale of certain fixed assets, restructuring charges and asset impairment charges) are non-GAAP financial measures that the Company uses to measure operational performance and assist with financial decision-making. Net Debt is defined as total debt (outstanding balance on the revolving credit facility plus financial lease obligations) less cash and cash equivalents. The leverage ratio of Net Debt to LTM Adjusted EBITDA is a financial measure that the Company believes is useful to investors and financial analysts in evaluating Quanex's leverage. In addition, with certain limited adjustments, this leverage ratio is the basis for a key covenant in the Company's credit agreement. Free Cash Flow is a nonGAAP measure calculated using cash provided by operating activities less capital expenditures. Free Cash Flow is measured before application of certain contractual commitments (including capital lease obligations), and accordingly is not a true measure of Quanex's residual cash flow available for discretionary expenditures. The Company believes that the presented non-GAAP measures provide a consistent basis for comparison between periods and will assist investors in understanding Quanex's financial performance when comparing results to other investment opportunities. The presented non-GAAP measures may not be the same as those used by other companies. The Company does not intend for this information to be considered in isolation or as a substitute for other measures prepared in accordance with U.S. GAAP.

## Forward Looking Statements

Statements that use the words "estimated," "expect," "could," "should," "believe," "will," "might," or similar words reflecting future expectations or beliefs are forward-looking statements. The forward-looking statements include, but are not limited to, the following: impacts from public health issues (including pandemics, such as the recent COVID-19 pandemic) on the economy and the demand for Quanex's products, the Company's future operating results, future financial condition, future uses of cash and other expenditures, expenses and tax rates, expectations relating to Quanex's industry, and the Company's future growth, including any guidance discussed in this press release. The statements and guidance set forth in this release are based on current expectations. Actual results or events may differ materially from this release. For a complete discussion of factors that may affect Quanex's future performance, please refer to the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2020, and the Company's Quarterly Reports on Form 10-Q under the sections entitled "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors". Any forward-looking statements in this press release are made as of the date hereof, and Quanex undertakes no obligation to update or revise any forward-looking statements to reflect new information or events.

## QUANEX BUILDING PRODUCTS CORPORATION

## CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data) (Unaudited)

|  | Three Months Ended July 31, |  |  |  | Nine Months Ended July 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2021 |  | 2020 |  | 2021 |  | 2020 |  |
| Net sales | \$ | 279,877 | \$ | 212,096 | \$ | 780,381 | \$ | 596,168 |
| Cost of sales |  | 219,866 |  | 162,427 |  | 604,723 |  | 469,586 |
| Selling, general and administrative |  | 27,766 |  | 21,973 |  | 88,299 |  | 62,818 |
| Restructuring charges |  | - |  | 73 |  | 39 |  | 477 |
| Depreciation and amortization |  | 10,683 |  | 11,060 |  | 32,543 |  | 35,851 |

Operating income
Interest expense
Other, net
Income before income taxes
Income tax expense
Net income

Earnings per common share, basic
Earnings per common share, diluted
Weighted average common shares outstanding:
Basic
Diluted

Cash dividends per share

|  | $\begin{array}{r} 21,562 \\ (597) \end{array}$ |  | $\begin{aligned} & 16,563 \\ & (1,165) \end{aligned}$ |  | $\begin{gathered} 54,777 \\ (1,988) \end{gathered}$ |  | $\begin{gathered} 27,436 \\ (4,310) \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 188 |  | (220) |  | 645 |  | 116 |
|  | $\begin{gathered} \hline 21,153 \\ (7,474) \\ \hline \end{gathered}$ |  | $\begin{aligned} & \hline 15,178 \\ & (4,345) \\ & \hline \end{aligned}$ |  | $\begin{gathered} \hline 53,434 \\ (17,352) \\ \hline \end{gathered}$ |  | $\begin{gathered} \hline 23,242 \\ (6,898) \end{gathered}$ |
| \$ | 13,679 | \$ | 10,833 | \$ | 36,082 | \$ | 16,344 |
| \$ | 0.41 | \$ | 0.33 | \$ | 1.09 | \$ | 0.50 |
| \$ | 0.41 | \$ | 0.33 | \$ | 1.08 | \$ | 0.50 |
|  | 33,359 |  | 32,610 |  | 33,194 |  | 32,716 |
|  | 33,650 |  | 32,739 |  | 33,518 |  | 32,845 |
| \$ | 0.08 | \$ | 0.08 | \$ | 0.24 | \$ | 0.24 |

## QUANEX BUILDING PRODUCTS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)


## LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable
Accrued liabilities
Income taxes payable
Current maturities of long-term debt
Current operating lease liabilities
Total current liabilities
Long-term debt
Noncurrent operating lease liabilities
Deferred pension and postretirement benefits
Deferred income taxes
Other liabilities
Total liabilities

| \$ | 79,167 | $\$$ |
| ---: | :--- | ---: |
| 52,751 |  | 77,335 |
| 1,327 |  | 38,289 |
| 8,465 |  |  |
| 839 |  | 692 |
| 8,270 |  | 7,459 |
|  | 142,354 |  |
| 72,439 |  | 130,240 |
| 47,371 |  | 416,728 |
| 10,765 |  | 10,973 |
| 25,252 |  | 19,116 |
| 15,622 |  | 13,946 |
|  |  | 335,826 |

Stockholders' equity:
Common stock
Additional paid-in-capital
Retained earnings
Accumulated other comprehensive loss
Treasury stock at cost
Total stockholders' equity
Total liabilities and stockholders' equity

| 373 | 373 |  |
| :---: | :---: | ---: |
| 253,662 |  | 253,458 |
| 241,582 | 213,517 |  |
|  | $(22,968)$ |  |
| $(67,260)$ |  |  |
|  |  | $(33,024)$ |
|  |  |  |

## Operating activities:

Net income
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization
32,543
Stock-based compensation
1,470
Deferred income tax
5,429
Other, net
5,485
762
Changes in assets and liabilities:
Increase in accounts receivable
$(8,277) \quad(1,852)$
(Increase) decrease in inventory
$(32,113) \quad 3,553$
(Increase) decrease in other current assets
Increase (decrease) in accounts payable
$(2,768)$

Increase (decrease) in accrued liabilities
1,600
,218
(Decrease) increase in income taxes payable
(Decrease) increase in deferred pension and postretirement benefits
12,521
$(1,878)$
$(5,158)$
$(7,611)$
(158)

107

Increase (decrease) in other long-term liabilities
962
573
Other, net
Cash provided by operating activities
(183)
(276)

## Investing activities:

Capital expenditures
Proceeds from disposition of capital assets
Cash used for investing activities

|  | $(16,006)$ |  | $(20,673)$ |
| :---: | :---: | :---: | :---: |
|  | 3,138 |  | 131 |
|  | $(12,868)$ |  | $(20,542)$ |
|  | - |  | 114,500 |
|  | $(45,000)$ |  | $(119,000)$ |
|  | (502) |  | (791) |
|  | $(8,017)$ |  | $(7,910)$ |
|  | 16,272 |  | 2,954 |
|  | (492) |  | (454) |
|  | $(5,741)$ |  | $(6,693)$ |
|  | $(43,480)$ |  | $(17,394)$ |
|  | 955 |  | 580 |
|  | $(7,958)$ |  | 10,205 |
|  | 51,621 |  | 30,868 |
| \$ | 43,663 | \$ | 41,073 |

## QUANEX BUILDING PRODUCTS CORPORATION FREE CASH FLOW AND NET DEBT RECONCILIATIONS <br> (In thousands) <br> (Unaudited)

The following table reconciles the Company's calculation of Free Cash Flow, a non-GAAP measure, to its most directly comparable GAAP measure. The Company defines Free Cash Flow as cash provided by operating activities less capital expenditures.

Cash provided by operating activities
Capital expenditures
Free Cash Flow

| Three Month | uly 31, | Nine Months Ended July 31, |  |
| :---: | :---: | :---: | :---: |
| 2021 | 2020 | 2021 | 2020 |
| 18,475 | \$45,089 | \$47,435 | \$47,561 |
| $(6,207)$ | $(4,360)$ | $(16,006)$ | $(20,673)$ |
| \$12,268 | \$40,729 | \$31,429 | \$26,888 |

The following table reconciles the Company's Net Debt which is defined as total debt principal of the Company plus finance lease obligations minus cash.

Revolving Credit Facility
Finance Lease Obligations
Total Debt ${ }^{(1)}$
Less: Cash and cash equivalents

## Net Debt

(1) Excludes outstanding letters of credit.

QUANEX BUILDING PRODUCTS CORPORATION
NON-GAAP FINANCIAL MEASURE DISCLOSURE
(In thousands, except per share data)
(Unaudited)

expense
Net income


Diluted earnings per \$ \$ $\quad 0.41$ \$ 0.33 share

## Three months ended July 31, 2020

Net sales
Cost of sales
Gross Margin
Gross Margin \%
Selling, general and administrative
Restructuring charges
Depreciation and amortization
Operating income (loss)
Depreciation and amortization
EBITDA
Restructuring charges
Adjusted EBITDA
Adjusted EBITDA Margin \%
Nine months ended July 31, 2021
Net sales
Cost of sales
Gross Margin
Gross Margin \%
Selling, general and administrative
Restructuring charges
Depreciation and amortization
Operating income (loss)
Depreciation and amortization
EBITDA
Loss on the damage of a plant
Loss on sale of plant
Restructuring charges
Adjusted EBITDA
Adjusted EBITDA Margin \%
Nine months ended July 31, 2020
Net sales
Cost of sales

Gross Margin
Gross Margin \%
Selling, general and administrative
Restructuring charges
Depreciation and amortization
Operating income (loss)
Depreciation and amortization
EBITDA
Transaction and advisory fees
Executive severance charges
Restructuring charges
Adjusted EBITDA
Adjusted EBITDA Margin \%

## NA Fenestration:

United States - fenestration International - fenestration United States - non-fenestration International - non-fenestration

| \$ | 122,386 | \$ | 38,265 | \$ | 51,925 | \$ | (480) | \$ | 212,096 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 92,639 |  | 25,845 |  | 44,218 |  | (275) |  | 162,427 |
|  | 29,747 |  | 12,420 |  | 7,707 |  | (205) |  | 49,669 |
|  | 24.3\% |  | 32.5\% |  | 14.8\% |  |  |  | 23.4\% |
|  | 11,922 |  | 4,748 |  | 4,634 |  | 669 |  | 21,973 |
|  | 71 |  | - |  | 2 |  | - |  | 73 |
|  | 5,371 |  | 2,307 |  | 3,264 |  | 118 |  | 11,060 |
|  | 12,383 |  | 5,365 |  | (193) |  | (992) |  | 16,563 |
|  | 5,371 |  | 2,307 |  | 3,264 |  | 118 |  | 11,060 |
|  | 17,754 |  | 7,672 |  | 3,071 |  | (874) |  | 27,623 |
|  | 71 |  | - |  | 2 |  | - |  | 73 |
| \$ | 17,825 | \$ | 7,672 | \$ | 3,073 | \$ | (874) | \$ | 27,696 |
|  | 14.6\% |  | 20.0\% |  | 5.9\% |  |  |  | 13.1\% |


| \$ | 422,077 | \$ | 181,862 | \$ | 179,492 | \$ | $(3,050)$ | \$ | 780,381 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 328,278 |  | 122,631 |  | 155,370 |  | $(1,556)$ |  | 604,723 |
|  | 93,799 |  | 59,231 |  | 24,122 |  | $(1,494)$ |  | 175,658 |
|  | 22.2\% |  | 32.6\% |  | 13.4\% |  |  |  | 22.5\% |
|  | 38,944 |  | 21,559 |  | 15,372 |  | 12,424 |  | 88,299 |
|  | 39 |  | - |  | - |  | - |  | 39 |
|  | 14,528 |  | 7,771 |  | 9,965 |  | 279 |  | 32,543 |
|  | 40,288 |  | 29,901 |  | $(1,215)$ |  | $(14,197)$ |  | 54,777 |
|  | 14,528 |  | 7,771 |  | 9,965 |  | 279 |  | 32,543 |
|  | 54,816 |  | 37,672 |  | 8,750 |  | $(13,918)$ |  | 87,320 |
|  | - |  | 307 |  | - |  | - |  | 307 |
|  | 375 |  | - |  | - |  | 1,439 |  | 1,814 |
|  | 39 |  | - |  | - |  | - |  | 39 |
| \$ | 55,230 | \$ | 37,979 | \$ | 8,750 | \$ | $(12,479)$ | \$ | 89,480 |
|  | 13.1\% |  | 20.9\% |  | 4.9\% |  |  |  | 11.5\% |


| \$ | 341,432 | \$ | 104,230 | \$ | 152,634 | \$ | $(2,128)$ | \$ | 596,168 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 266,489 |  | 72,055 |  | 132,259 |  | $(1,217)$ |  | 469,586 |
|  | 74,943 |  | 32,175 |  | 20,375 |  | (911) |  | 126,582 |
|  | 21.9\% |  | 30.9\% |  | 13.3\% |  |  |  | 21.2\% |
|  | 34,962 |  | 15,990 |  | 13,468 |  | $(1,602)$ |  | 62,818 |
|  | 228 |  | - |  | 249 |  | - |  | 477 |
|  | 18,311 |  | 7,045 |  | 10,139 |  | 356 |  | 35,851 |
|  | 21,442 |  | 9,140 |  | $(3,481)$ |  | 335 |  | 27,436 |
|  | 18,311 |  | 7,045 |  | 10,139 |  | 356 |  | 35,851 |
|  | 39,753 |  | 16,185 |  | 6,658 |  | 691 |  | 63,287 |
|  | - |  | - |  | - |  | 55 |  | 55 |
|  | - |  | - |  | - |  | 1,343 |  | 1,343 |
|  | 228 |  | - |  | 249 |  | - |  | 477 |
| \$ | 39,981 | \$ | 16,185 | \$ | 6,907 | \$ | 2,089 | \$ | 65,162 |
|  | 11.7\% |  | 15.5\% |  | 4.5\% |  |  |  | 10.9\% |

## QUANEX BUILDING PRODUCTS CORPORATION

SALES ANALYSIS
(In thousands)
(Unaudited)

| Three Months Ended |  |  |  | Nine Months Ended |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 31,2021 | July 31, 2020 |  | July 31, 2021 |  | July 31, 2020 |  |
| \$ | 129,291 | \$ | 109,455 | \$ | 369,809 | \$ | 302,094 |
|  | 9,581 |  | 6,696 |  | 25,756 |  | 19,284 |
|  | 5,853 |  | 4,845 |  | 17,543 |  | 13,779 |
|  | 3,093 |  | 1,390 |  | 8,969 |  | 6,275 |
| \$ | 147,818 | \$ | 122,386 | \$ | 422,077 | \$ | 341,432 |

Nine Months Ended July 31, 2021 July 31, 2020

## EU Fenestration ${ }^{(1)}$

International - fenestration
International - non-fenestration

## NA Cabinet Components:

United States - fenestration
United States - non-fenestration
International - non-fenestration

## Unallocated Corporate \& Other:

Eliminations

## Net Sales

| \$ | 54,883 | \$ | 31,904 | \$ | 147,072 | \$ | 87,732 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 16,231 |  | 6,361 |  | 34,790 |  | 16,498 |
| \$ | 71,114 | \$ | 38,265 | \$ | 181,862 | \$ | 104,230 |
| \$ | 3,240 | \$ | 2,666 | \$ | 9,711 | \$ | 8,461 |
|  | 57,418 |  | 48,849 |  | 168,308 |  | 142,838 |
|  | 1,278 |  | 410 |  | 1,473 |  | 1,335 |
| \$ | 61,936 | \$ | 51,925 | \$ | 179,492 | \$ | 152,634 |


| \$ | (991) | \$ | (480) | \$ | $(3,050)$ | \$ | $(2,128)$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| \$ | (991) | \$ | (480) | \$ | $(3,050)$ | \$ | $(2,128)$ |
| \$ | 279,877 | \$ | 212,096 | \$ | 780,381 | \$ | 596,168 |

(1) Reflects increase of $\$ 4.1$ million and $\$ 8.6$ million in revenue associated with foreign currency exchange rate impacts for the three and nine months ended July 31, 2021, respectively.

